Researchers are working on new treatments for migraine attacks that cause fewer adverse reactions, including strokes, heart attacks and cognitive problems, a British migraine expert said. Tonabersat, which belongs to a new class of medicines called gap-junction blockers, is undergoing early clinical trials as a preventive medication for the condition. Other compounds that block the calcitonin gene-related peptide -- found at elevated levels in the brains of migraine patients -- are being developed to relieve symptoms without constricting blood vessels.

Related Summaries